- Home
- Apac Whole Exome Sequencing Market
APAC Whole Exome Sequencing Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-405 | No of pages: 208 | Format:
Asia-Pacific whole exome sequencing (WES) market is projected to register a substantial CAGR of 18.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Whole Exome Sequencing (WES) Market, By Component (Second generation sequencing and Third-Generation sequencing), Product and Service (systems, kits and services), Application (Drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others ), End User (pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others), Distribution Channel (direct trade, retail sales and others), Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the Asia-Pacific Whole Exome Sequencing (WES) market are:
Growing usage of targeted sequencing methods
Increase in the adoption of whole exome sequencing (WES)
Asia-Pacific Whole Exome Sequencing (WES) market is categorized into four notable segment which is Component, Product and Service, Application, End User and Distribution Channel.
On the basis of component, the global whole exome sequencing (WES) market is segmented into second generation sequencing and third-generation sequencing.
On the basis of Product and Service, the global whole exome sequencing (WES) market is segmented into systems, kits and services.
On the basis of Application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
On the basis of End user, the global whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
On the basis of Distribution Channel, the global whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.
Market Players:
The key market players for Asia-Pacific whole exome sequencing (WES) market are listed below:
Meridian
Merck KGaA
SOPHiA GENETICS
Azenta U.S. Inc.
CD Genomics
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF ASIA PACIFIC WHOLE EXOME SEQUENCING (WES) MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 PRODUCT TYPE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 57
4.1 PORTERS FIVE FORCES 58
4.2 PESTEL ANALYSIS 59
4.3 INDUSTRIAL INSIGHTS: 60
4.4 CONCLUSION 61
5 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET: REGULATIONS 62
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 66
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 66
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 66
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 67
6.2 RESTRAINTS 68
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 68
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 68
6.3 OPPORTUNITIES 69
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 69
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 69
6.4 CHALLENGES 70
6.4.1 LACK OF SKILLED PROFESSIONALS 70
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 70
7 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 71
7.1 OVERVIEW 72
7.2 SECOND-GENERATION SEQUENCING 75
7.2.1 SEQUENCING BY SYNTHESIS (SBS) 76
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 76
7.3 THIRD-GENERATION SEQUENCING 77
8 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 78
8.1 OVERVIEW 79
8.2 SYSTEMS 82
8.2.1 HISEQ SERIES 83
8.2.1.1 HISEQ 2500 83
8.2.1.2 HISEQ 1500 83
8.2.2 MISEQ SERIES 83
8.2.3 ION TORRENT PLATFORMS 84
8.2.3.1 ION PROTON 84
8.2.3.2 ION PGM 84
8.2.4 OTHERS 84
8.3 KITS 84
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 85
8.3.2 LIBRARY PREPARATION KITS 85
8.3.3 TARGET ENRICHMENT KITS 86
8.3.4 OTHERS 86
8.4 SERVICES 86
8.4.1 SEQUENCING SERVICES 87
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 87
8.4.3 OTHERS 87
9 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 88
9.1 OVERVIEW 89
9.2 DRUG DISCOVERY AND DEVELOPMENT 92
9.3 AGRICULTURE & ANIMAL RESEARCH 93
9.4 DIAGNOSTICS 93
9.5 PERSONALIZED MEDICINE 94
9.6 OTHERS 95
10 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET, BY END USER 96
10.1 OVERVIEW 97
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
10.3 ACADEMIC & RESEARCH INSTITUTES 101
10.4 HOSPITALS AND CLINICS 101
10.5 CLINICAL LABORATORIES 102
10.6 OTHERS 103
11 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 104
11.1 OVERVIEW 105
11.2 DIRECT TRADE 108
11.3 RETAIL SALES 108
11.4 OTHERS 110
12 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET, BY REGION 111
12.1 ASIA-PACIFIC 112
12.1.1 CHINA 120
12.1.2 JAPAN 123
12.1.3 INDIA 126
12.1.4 SOUTH KOREA 129
12.1.5 AUSTRALIA 133
12.1.6 SINGAPORE 137
12.1.7 THAILAND 141
12.1.8 INDONESIA 145
12.1.9 PHILIPPINES 149
12.1.10 MALAYSIA 153
12.1.11 VIETNAM 157
12.1.12 REST OF ASIA-PACIFIC 161
13 ASIA PACIFIC WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 162
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 162
14 COMPANY PROFILE 163
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 163
14.1.1 COMPANY SNAPSHOT 163
14.1.2 REVENUE ANALYSIS 163
14.1.3 COM PANY SHARE ANALYSIS 164
14.1.4 PRODUCT PORTFOLIO 164
14.1.5 RECENT DEVELOPMENTS 164
14.2 MERCK KGAA 166
14.2.1 COMPANY SNAPSHOT 166
14.2.2 REVENUE ANALYSIS 166
14.2.3 COM PANY SHARE ANALYSIS 167
14.2.4 PRODUCT PORTFOLIO 167
14.2.5 RECENT DEVELOPMENTS 167
14.3 EXODX (A PART OF BIO-TECHNE) 168
14.3.1 COMPANY SNAPSHOT 168
14.3.2 REVENUE ANALYSIS 168
14.3.3 COM PANY SHARE ANALYSIS 169
14.3.4 PRODUCT PORTFOLIO 169
14.3.5 RECENT DEVELOPMENTS 169
14.4 THERMO FISHER SCIENTIFIC INC. 170
14.4.1 COMPANY SNAPSHOT 170
14.4.2 REVENUE ANALYSIS 170
14.4.3 COM PANY SHARE ANALYSIS 171
14.4.4 PRODUCT PORTFOLIO 171
14.4.5 RECENT DEVELOPMENTS 171
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 172
14.5.1 COMPANY SNAPSHOT 172
14.5.2 REVENUE ANALYSIS 172
14.5.3 COM PANY SHARE ANALYSIS 173
14.5.4 PRODUCT PORTFOLIO 173
14.5.5 RECENT DEVELOPMENTS 173
14.6 AZENTA US, INC. 175
14.6.1 COMPANY SNAPSHOT 175
14.6.2 PRODUCT PORTFOLIO 175
14.6.3 RECENT DEVELOPMENTS 175
14.7 BECKMAN COULTER, INC 177
14.7.1 COMPANY SNAPSHOT 177
14.7.2 REVENUE ANALYSIS 177
14.7.3 PRODUCT PORTFOLIO 178
14.7.4 RECENT DEVELOPMENTS 178
14.8 BIONEER CORPORATION 179
14.8.1 COMPANY SNAPSHOT 179
14.8.2 REVENUE ANALYSIS 179
14.8.3 PRODUCT PORTFOLIO 180
14.8.4 RECENT DEVELOPMENTS 180
14.9 CD GENOMICS 181
14.9.1 COMPANY SNAPSHOT 181
14.9.2 PRODUCT PORTFOLIO 181
14.9.3 RECENT DEVELOPMENTS 181
14.10 CEGAT GMBH 182
14.10.1 COMPANY SNAPSHOT 182
14.10.2 PRODUCT PORTFOLIO 182
14.10.3 RECENT DEVELOPMENTS 182
14.11 EUROFINS SCIENTIFIC 183
14.11.1 COMPANY SNAPSHOT 183
14.11.2 REVENUE ANALYSIS 183
14.11.3 PRODUCT PORTFOLIO 184
14.11.4 RECENT DEVELOPMENTS 184
14.12 GENEDX, LLC 185
14.12.1 COMPANY SNAPSHOT 185
14.12.2 PRODUCT PORTFOLIO 185
14.12.3 RECENT DEVELOPMENTS 185
14.13 GENEFIRST LIMITED. 187
14.13.1 COMPANY SNAPSHOT 187
14.13.2 PRODUCT PORTFOLIO 187
14.13.3 RECENT DEVELOPMENTS 187
14.14 ILLUMINA, INC 189
14.14.1 COMPANY SNAPSHOT 189
14.14.2 REVENUE ANALYSIS 189
14.14.3 PRODUCT PORTFOLIO 190
14.14.4 RECENT DEVELOPMENTS 190
14.15 INTEGRATED DNA TECHNOLOGIES, INC. 192
14.15.1 COMPANY SNAPSHOT 192
14.15.2 PRODUCT PORTFOLIO 192
14.15.3 RECENT DEVELOPMENTS 192
14.16 MERIDIAN BIOSCIENCE, INC. 194
14.16.1 COMPANY SNAPSHOT 194
14.16.2 REVENUE ANALYSIS 194
14.16.3 PRODUCT PORTFOLIO 195
14.16.4 RECENT DEVELOPMENTS 195
14.17 PSOMAGEN 196
14.17.1 COMPANY SNAPSHOT 196
14.17.2 REVENUE ANALYSIS 196
14.17.3 PRODUCT PORTFOLIO 196
14.17.4 RECENT DEVELOPMENTS 197
14.18 QIAGEN 198
14.18.1 COMPANY SNAPSHOT 198
14.18.2 REVENUE ANALYSIS 198
14.18.3 PRODUCT PORTFOLIO 199
14.18.4 RECENT DEVELOPMENTS 199
14.19 SOPHIA GENETICS 200
14.19.1 COMPANY SNAPSHOT 200
14.19.2 REVENUE ANALYSIS 200
14.19.3 PRODUCT PORTFOLIO 201
14.19.4 RECENT DEVELOPMENTS 201
14.20 TWIST BIOSCIENCE 202
14.20.1 COMPANY SNAPSHOT 202
14.20.2 REVENUE ANALYSIS 202
14.20.3 PRODUCT PORTFOLIO 203
14.20.4 RECENT DEVELOPMENTS 203
15 QUESTIONNAIRE 205
16 RELATED REPORTS 208
Segmentation
Short Description
Asia-Pacific Whole Exome Sequencing Market, Component (Whole Exome Sequencing, Second-Generation Sequencing, Third-Generation Sequencing), Product And Services (Systems, Kits, Services), Application (Diagnostics, Drug Discovery And Development, Personalized Medicine, Agriculture & Animal Research, Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, Others), Distribution Channel (Direct Trade, Retail Sales, Others). Industry Trends and Forecast to 2029.
Market Definition:
Whole exome sequencing is a genomic technique indicated for sequencing of all the protein-coding region of genes in a genome. Whole exome sequencing (WES) is available to physicians and patients who are looking for a unifying diagnosis of multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exon (or protein-coding) regions of an individuals genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES (Whole-exome sequencing). The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants making this method a cost-effective alternative to whole-genome sequencing.
Exome sequencing is used across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.
Market Segmentation:
Asia-Pacific whole exome sequencing market is categorized into five notable segments which are based on component, product and service, application, end user and distribution channel. In 2022, second generation sequencing segment is expected to dominate the market due to increasing use of personalized medicine and growing adoption and demand of whole exome sequencing.
On the basis of component, the whole exome sequencing market is segmented into second generation sequencing and third-generation sequencing.
On the basis of product and service, the whole exome sequencing market is segmented into systems, kits and services.
On the basis of application, the whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
On the basis of end user, the whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
On the basis of distribution channel, the whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.
Market Players
The key market players for the Asia-Pacific whole exome sequencing market are listed below:
Beckman Coulter, Inc.
BIONEER CORPORATION
Eurofins Scientific
ExoDx (a part of Bio-Techne)
FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd)
QIAGEN
GeneFirst Limited
Illumina, Inc.
Meridian
Merck KGaA
SOPHiA GENETICS
Azenta Life Sciences
CD Genomics
Twist Bioscience
Thermo Fisher Scientific Inc.
PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
Psomagen
Integrated DNA Technologies, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.